Literature DB >> 12704142

The levels and patterns of cytokines produced by CD4 T lymphocytes of BALB/c mice infected with Leishmania major by inoculation into the ear dermis depend on the infectiousness and size of the inoculum.

Thierry Lang1, Nathalie Courret, Jean-Hervé Colle, Geneviève Milon, Jean-Claude Antoine.   

Abstract

The production of cytokines by CD4 lymph node T lymphocytes derived from BALB/c mice recently infected in the ear dermis with high (10(6) parasites) or low (10(3) parasites) doses of Leishmania major metacyclic promastigotes (MP) was examined over a 3-week period following inoculation. Results were compared with those obtained when mice were injected with less infectious parasite populations, namely, stationary-phase or log-phase promastigotes (LP). Cells were purified 16 h and 3, 8, and 19 days after inoculation, and the amounts of gamma interferon (IFN-gamma) and interleukin-4 (IL-4) released in response to LACK (Leishmania homolog of receptors for activated C kinase) or total L. major antigens were assessed. We found that LACK-reactive T cells from mice inoculated with a high dose of parasites first produced IFN-gamma and later on IL-4; the level of IFN-gamma produced early by these cells was dependent upon the stage of the promastigotes inoculated, the highest level being reached with cells recovered from mice inoculated with the least infectious parasites, LP; sequential production of IFN-gamma and then of IL-4 also characterized L. major antigen-reactive CD4 T cells, suggesting that the early production of IFN-gamma does not impede the subsequent rise of IL-4 and finally the expansion of the parasites; after low-dose inoculation of MP, cutaneous lesions developed with kinetics similar to that of lesions induced after inoculation of 10(6) LP, but in this case CD4 T lymphocytes did not release IFN-gamma or IL-4 in the presence of LACK and neither cytokine was produced in response to L. major antigens before the onset of lesion signs. These results suggest the existence of a discreet phase in terms of CD4 T-cell reactivity for at least the first 8 days following inoculation, a time period during which parasites are able to grow moderately. In conclusion, the levels and profiles of cytokines produced by Leishmania-specific CD4 T lymphocytes clearly depend on both the stage of differentiation and number of parasites used for inoculation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704142      PMCID: PMC153224          DOI: 10.1128/IAI.71.5.2674-2683.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

1.  A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity.

Authors:  Y Belkaid; S Mendez; R Lira; N Kadambi; G Milon; D Sacks
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

2.  In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease.

Authors:  H Himmelrich; P Launois; I Maillard; T Biedermann; F Tacchini-Cottier; R M Locksley; M Röcken; J A Louis
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

3.  Expression cloning of a protective Leishmania antigen.

Authors:  E Mougneau; F Altare; A E Wakil; S Zheng; T Coppola; Z E Wang; R Waldmann; R M Locksley; N Glaichenhaus
Journal:  Science       Date:  1995-04-28       Impact factor: 47.728

4.  An immunomodulatory function for neutrophils during the induction of a CD4+ Th2 response in BALB/c mice infected with Leishmania major.

Authors:  F Tacchini-Cottier; C Zweifel; Y Belkaid; C Mukankundiye; M Vasei; P Launois; G Milon; J A Louis
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

5.  Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages.

Authors:  E Prina; T Lang; N Glaichenhaus; J C Antoine
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

Review 6.  The regulation of immunity to Leishmania major.

Authors:  S L Reiner; R M Locksley
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

Review 7.  Progressive disease or protective immunity to Leishmania major infection: the result of a network of stimulatory and inhibitory interactions.

Authors:  R Etges; I Müller
Journal:  J Mol Med (Berl)       Date:  1998-05       Impact factor: 4.599

8.  Susceptibility to Leishmania major infection in interleukin-4-deficient mice.

Authors:  N Noben-Trauth; P Kropf; I Müller
Journal:  Science       Date:  1996-02-16       Impact factor: 47.728

9.  In susceptible mice, Leishmania major induce very rapid interleukin-4 production by CD4+ T cells which are NK1.1-.

Authors:  P Launois; T Ohteki; K Swihart; H R MacDonald; J A Louis
Journal:  Eur J Immunol       Date:  1995-12       Impact factor: 5.532

10.  Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice.

Authors:  L Carrera; R T Gazzinelli; R Badolato; S Hieny; W Muller; R Kuhn; D L Sacks
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

View more
  8 in total

1.  Intralesional uridine-5'-triphosphate (UTP) treatment induced resistance to Leishmania amazonensis infection by boosting Th1 immune responses and reactive oxygen species production.

Authors:  Camila Marques-da-Silva; Mariana M Chaves; Maria Luiza Thorstenberg; Vanessa R Figliuolo; Flávia S Vieira; Suzana P Chaves; José Roberto Meyer-Fernandes; Bartira Rossi-Bergmann; Luiz Eduardo Baggio Savio; Robson Coutinho-Silva
Journal:  Purinergic Signal       Date:  2018-04-21       Impact factor: 3.765

2.  Effect of ambient temperature on the clinical manifestations of experimental diffuse cutaneous leishmaniasis in a rodent model.

Authors:  Laura Quiñonez-Díaz; Javier Mancilla-Ramírez; Miroslava Avila-García; Juana Ortiz-Avalos; Angélica Berron; Susana González; Yuriria Paredes; Norma Galindo-Sevilla
Journal:  Vector Borne Zoonotic Dis       Date:  2012-05-31       Impact factor: 2.133

3.  Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice.

Authors:  Ghassem Solgi; Amina Kariminia; Khossor Abdi; Majid Darabi; Behnaz Ghareghozloo
Journal:  Korean J Parasitol       Date:  2006-03       Impact factor: 1.341

4.  Complement receptor 3 deficiency influences lesion progression during Leishmania major infection in BALB/c mice.

Authors:  Cristina R Carter; James P Whitcomb; Jessica A Campbell; Rami M Mukbel; Mary Ann McDowell
Journal:  Infect Immun       Date:  2009-09-21       Impact factor: 3.441

5.  Nitric oxide production by Peromyscus yucatanicus (Rodentia) infected with Leishmania (Leishmania) mexicana.

Authors:  Elsy Nalleli Loría-Cervera; Erika Ivett Sosa-Bibiano; Liliana Estefanía Villanueva-Lizama; Nicole Raymonde Van Wynsberghe; Silvia Beatriz Canto-Lara; José Luis Batún-Cutz; Fernando José Andrade-Narváez
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-04       Impact factor: 2.743

Review 6.  Animal models for the study of leishmaniasis immunology.

Authors:  Elsy Nalleli Loría-Cervera; Fernando José Andrade-Narváez
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Jan-Feb       Impact factor: 1.846

Review 7.  Study of Leishmania pathogenesis in mice: experimental considerations.

Authors:  Corinne Loeuillet; Anne-Laure Bañuls; Mallorie Hide
Journal:  Parasit Vectors       Date:  2016-03-11       Impact factor: 3.876

8.  Fe3O4@Bio-MOF Nanoparticles Combined with Artemisinin, Glucantime®, or Shark Cartilage Extract on Iranian Strain of Leishmania major (MRHO/IR/75/ER): An In-Vitro and In-Vivo Study.

Authors:  Fatemeh Ghafarifar; Soheila Molaie; Reza Abazari; Zoheir-Mohammad Hasan; Masoud Foroutan
Journal:  Iran J Parasitol       Date:  2020 Oct-Dec       Impact factor: 1.012

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.